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Abstract
A general obstacle for clinical cell preparations is limited purity, which causes variability in the quality and potency of cell
products and might be responsible for negative side effects due to unwanted contaminants. Highly pure populations can
be obtained best using positive selection techniques. However, in many cases target cell populations need to be segregated
from other cells by combinations of multiple markers, which is still difficult to achieve – especially for clinical cell products.
Therefore, we have generated low-affinity antibody-derived Fab-fragments, which stain like parental antibodies when
multimerized via Strep-tag and Strep-Tactin, but can subsequently be removed entirely from the target cell population. Such
reagents can be generated for virtually any antigen and can be used for sequential positive enrichment steps via
paramagnetic beads. First protocols for multiparameter enrichment of two clinically relevant cell populations, CD4
high/
CD25
high/CD45RA
high ‘regulatory T cells’ and CD8
high/CD62L
high/CD45RA
neg ‘central memory T cells’, have been established
to determine quality and efficacy parameters of this novel technology, which should have broad applicability for clinical cell
sorting as well as basic research.
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Introduction
Cell therapy has proven to be highly effective for the treatment
of a number of human diseases. For example, primary
immunodeficiencies can be cured by hematopoietic stem cell
transplantation (HSCT), and some patients with leukemia can be
brought to complete remission by allogeneic HSCT alone, or
combined with donor lymphocyte infusion (DLI). In some clinical
settings, the adoptive transfer of virus-specific T cells can very
effectively reconstitute immunity in immunocompromised pa-
tients, and prevent or treat life-threatening complications caused
by cytomegalovirus reactivation [1,2,3] or lymphoproliferative
diseases mediated by Epstein-Barr-Virus [4,5]. Similarly, tumor-
specific T cells, either from autologous tumor-infiltrating lympho-
cytes or engineered in vitro, are promising candidates for improved
therapies for cancer [6].
Despite these interesting clinical observations, a broader transfer
of cell therapy to clinical applications has remained a challenge.
This is in part due to the problem that cell populations known to
mediate clinical effects should best be enriched to high purities,
since ‘unwanted’ contaminating cells can cause harmful and
sometimes life-threatening side effects such as graft-versus-host-
diseases (GvHD) mediated by alloreactive T cells. Very low
numbers of adoptively transferred T cells can contribute to
beneficial clinical effects [7], and similar rules will also apply to cell
populations that mediate negative side effects. Therefore,
providing the highest possible purities of well-defined cell
preparations applicable for therapy is a key to making these
promising treatments more effective and predictable, as well as to
lower the risk of potential side effects.
Current methods for surface marker-mediated clinical cell
purification usually rely on single parameters (e.g. CD34, MHC-
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directly ex vivo or expanded after in vitro cell culture – the use of a
combination of different surface markers is necessary to truly
segregate a defined subpopulation. For example, naturally
occurring regulatory T cells (nTregs) represent a promising cell
population for preventing acute GvHD after allogeneic HSCT
[8,9,10] or the development of several autoimmune diseases
[11,12]. Regulatory T cells lack a single cell-specific surface
marker, therefore most current protocols for enrichment of nTregs
from primary blood specimens or in vitro-expanded sources employ
multiple markers such as CD4 and the constitutively expressed
high-affinity IL-2 receptor a-chain (CD25), to reduce heterogene-
ity. However, CD25 is also expressed on many non-regulatory
cells, which include recently activated effector and memory T
cells. Therefore, complex combinatorial staining patterns, com-
prising combinations of CD4, CD25, CD127 and CD45RA
[13,14], have been necessary to more precisely identify and
separate this clinically relevant T cell subset. Similarly, T cells with
a central memory phenotype (TCM) can only be segregated from
other subsets by combinatorial surface marker expression patterns
(CD3
+, CD62L
+, CD45RO
+, CD45RA
2). TCM exhibit superb
characteristics for adoptive T cell transfer due to their longevity in
vivo, and cell cultures derived from highly purified TCM have
enhanced persistence after adoptive transfer [15]. Thus, the TCM
subset is an interesting source for adoptive transfer of primary
(unmanipulated) T cells as well as for genetic engineering to
express defined recombinant T cell receptors (TCRs) or chimeric
antigen-receptors (CARs) prior to administration [16,17].
Currently available surface marker-based cell separation
techniques usually utilize paramagnetic beads. Thereby, positive
enrichment strategies using directly labeled target populations give
the highest yields and purities. Yet, a more stringent purification
that requires the combination of several markers cannot be
achieved by positive selection alone. Therefore, protocols
combining initial depletion of most unwanted cell populations by
negative selection followed by a final positive enrichment step have
been developed, which in some cases provide quite pure cell
products. Unfortunately, the large number of surface markers and
corresponding clinical-grade reagents required for depletion
strongly interferes with the feasibility of this strategy for clinical
applications. In addition, after positive selection, both the labeling
reagents and the beads usually remain on the enriched cells,
potentially manipulating the isolated cell population or negatively
impacting its functionality and/or viability [18,19]. Particularly
with respect to clinical cell sorting, lingering cell labels pose
substantial regulatory hurdles for the treatment of patients with
such cell products. In order to circumvent the problems of positive
selection, many clinical cell-processing procedures have been
changed to exclusively employ depletion reagents. Unfortunately,
under such conditions target cell purities are often poor, and
depletion methods commonly require a complicated cocktail of
different antibodies, making their production and application
laborious and expensive.
We have recently introduced the MHC-Streptamer technology
for the positive selection of antigen-specific CD8
+ T cells [18].
This simple cell purification procedure allows the release and
complete removal of all components of the selection marker from
the purified cell population. The major advantage of this strategy
is that positive cell purification can be applied to obtain highly
enriched antigen-specific T cells that have been classified by
regulatory authorities as minimally manipulated cell products,
which facilitates substantially the generation and usage of such
cells for clinical applications. We hypothesized that the removal of
positive selection labels after a purification step could be applied to
any cell surface marker, allowing purification of cell populations
that can only be defined by multiple parameters via serial positive
enrichment. Here we describe a novel method, so-called Fab-
Streptamers, which fulfills exactly these criteria.
Materials and Methods
Blood samples
Fresh PBMCs were generated from either peripheral blood or
buffy-coats by centrifugation over Biocoll separating solution.
Peripheral blood was obtained from healthy adult donors of both
sexes at the Institute of Medical Microbiology, Immunology and
Hygiene (Technical University Munich), and buffy-coats were
obtained from autologous male or female blood donors (17–82
years old) at the Institute for Anesthesiology, German Heart
Centre Munich (State of Bavaria and Technical University
Munich). Written informed consent was obtained from the donors,
and usage of the blood samples was approved according to
national law by the local Institutional Review Board (Ethikkom-
mission der Medizinischen Fakulta ¨t der Technischen Universita ¨t
Mu ¨nchen).
Production of Fab-multimers (Cloning, Expression,
Purification, Multimerization)
Monomeric Fab-fragments originating from monoclonal anti-
bodies [20] were generated by gene synthesis (Invitrogen) or by
PCR-based cloning of the variable region from hybridomas [21]
(parental clones aCD3: OKT3; aCD4: 13B8.2; aCD8: OKT8;
aCD25: FRT5; aCD62L: DREG56; aCD45RA: MEM56). After
generation of cDNA, the hypervariable sequences of heavy and
light chains were amplified as described before [21] and verified by
sequencing. The obtained variable (V) domains from the heavy
(VH) and light (VL) chains were cloned on a pENTRY-IBA50
StarGate vector allowing the combination with sequences coding
for the constant domains of human subclass IgG1/k [22] in a
subsequent recombination step. The heavy chains were carboxy-
terminally fused with a OneSTrEPtag affinity tag (IBA). All
combinatorial cloning was done using the StarGate cloning system
(IBA) with fusion vectors adapted for periplasmatic Fab expres-
sion. The cistron organization has been described before [23]; a
schematic overview is depicted in Fig. S1. In some cases
mutagenesis PCR was applied to introduce amino acid substitu-
tions within the non-hypervariable framework regions. Following
cloning, both the chimeric heavy and the light chain were
periplasmatically expressed in E. coli K-12 strain JM83 allowing
protein folding, disulfide bond formation and assembly of the Fab
heterodimer [24]. Fab fragments were produced in 2L LB shaking
cultures supplemented with 100 mg/ml ampicillin (Amp). Recom-
binant protein was harvested 3 hours post anhydrotretracyclin
(500 mg/ml) induced gene expression, periplasmic extract was
prepared as described before [25] and Fab-fragments were
purified by Strep-tag/Strep-Tactin affinity chromatography via a
Strep-Tactin Superflow column (IBA) and stored in PBS pH 7.5
[26].
One mg Fab-multimer consisting of monomeric Fab-OneS-
TrEPtagged fragment and Strep-Tactin labeled either with
phycoerythrine or allophycocyanin was used to stain up to
5610
6 cells.
FACS Analysis
For FACS analysis, 5610
6 PBMCs were incubated with the
multimeric Fab-Strep-Tactin-complexes (Fab-multimers) for
20 minutes at 4uC. Combined antibody stainings were performed
by concomitant application of the respective antibodies: anti-CD3
Clinical Multiparameter Cell Sorting
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(HI100) and anti-CD62L (DREG56, all from eBiosciences), anti-
CD25 (ACT-1), anti-CD45RO (UCHL1) and anti-CD69 (FN50,
all from Dako Cytomation) and anti-CD30 (Ber-H83, Becton
Dickinson). After surface staining, cells were washed and
subsequently stained with propidium iodide (Molecular Probes)
for live/dead cell discrimination.
For intranuclear FoxP3 staining, isolated cells were incubated
with EMA, permeabilized and fixated as recommended by the
manufacturer (eBioscience). Staining with anti-FoxP3 antibody
(PCH101, eBioscience) was performed for 30 min at 4uC. Data
were collected by flow cytometry on a CyAn ADP Lx (Beckman
Coulter) and analyzed with FlowJo software (TreeStar).
Sequential magnetic enrichment
For the sequential magnetic enrichment of CD4
+CD25
+CD45RA
+
triple-positive cells, 1610
8 PBMCs were first incubated with Strep-
Tactin-functionalized (in total 15 mg Strep-Tactin was used) magnetic
beads (1 mm approximate diameter) coated overnight with the
reversible CD4 Fab-monomers. Subsequently, CD4
+ cells were
isolated by retention on a NdFeB permanent magnet (Q-60-30-15-
N40 from Supermagnete, Gottmadingen, Germany). Non-retained
cells were removed, and the magnet was removed and then reapplied
after washing the retained cells in 5 ml heparinized PBS containing
0.5% BSA (w/v). This procedure was repeated five times and the
CD4
+ cells were then completely liberated from the beads and Fab-
fragments by addition of 1 mM D-biotin (applied twice) and washing
(twice, including a 10 min incubation time). In two further consecutive
enrichment steps, CD25- or CD45RA-coated beads were used to
isolate either CD4
+CD25
+ or triple positive cells from the pre-
enriched CD4
+ or CD4
+CD25
+ cell pool respectively, and further
processed as described above. CD8
+ TCM (CD8
+CD62L
+CD45RA-
neg)wereenriched with CD8- and CD62LFab-functionalized beadsas
described above. CD45RA Fab-beads were used as last step to deplete
CD45RA-positive cells in the CD8
+CD62L
+ pre-enriched prepara-
tion. For determination of the final yields, absolute cell numbers were
determined by counting appropriate dilutions of the final positive
fraction in a Neubauer counting chamber. Live/dead discrimination
was performed using Trypane blue staining.
Suppression assay
Suppression of effector T cell proliferation was determined in a
CFSE dilution assay after polyclonal anti-CD3 stimulation
(0.5 mg/ml, clone OKT3) at a Treg:T responder cell ratio of
2:1. For the proliferation assay effector cells were labeled with
2.5 mM CFSE (Molecular Probes), and 2610
4 effector T cells
(along with 4610
4 Treg cells and 1610
5 autologous irradiated
feeder cells) were plated in 96-well plates in supplemented RPMI
(Gibco). After 5 days, CFSE signal dilution was measured on a
CyAn ADP Lx cytometer (Beckman Coulter).
Results
Principle of reversible Fab-multimer staining
We hypothesized that multiparameter cell sorting by serial
positive enrichment could be achieved if the specific cell label used
for each enrichment step could be removed before entering the
next purification cycle (Fig. 1a). Since most approaches for specific
labeling of cell surface markers rely on antibody staining, we
developed reversible staining probes based on existing reagents.
Antigen specificity of an antibody is determined within the
variable region of its Fab portion, which contains identical binding
regions displayed in 2 (IgG, IgA, IgE) or 10 (IgM) copies,
indicating the role of multiple interactions with the antigen to
enhance binding avidity. We speculated that in cases where
monomeric Fab-molecules are of such low affinity that they alone
cannot stably bind to a given antigen, the associated avidity gain
by multimerization should enable such probes to be used for
specific cell labeling [27]. Furthermore, if multimerization of such
Fab-reagents could subsequently be reversed by targeted disrup-
tion of the complex, the low-affinity Fab-monomers should
spontaneously dissociate from the cell surface, leaving purified
cells fully liberated from all labeling components (Fig. 1b), thereby
allowing the transfer of these cells to additional (serial) positive
enrichment steps.
To demonstrate first ‘proof of concept’ of this reversible Fab-
multimer strategy, we used the well-characterized huHRS3 Fab-
fragment directed against CD30 [24]. This fragment was derived
from the parental monoclonal antibody HRS3 by grafting the
murine CDRs onto a human immunoglobulin consensus
sequence, which initially resulted in a functional binding site for
CD30 but was accompanied by a substantial loss in affinity
(KD=278661 nM from equilibrium analysis) [24]. In order to
introduce a multimerization site, the heavy chain of the Fab-
fragment was genetically fused to the OneSTrEP-tag sequence
(Strep-tag), and expressed together with the light chain in the
periplasm of E. coli [24]. The functionally assembled Fab-
fragments were then purified by affinity chromatography on a
Strep-Tactin resin and subsequently multimerized in the presence
of phycoerythrin-labeled Strep-Tactin. Notably, this interaction is
reversible upon addition of D-biotin (or its derivatives) as a
competing ligand (Fig. 1b) [26].
As shown in Fig. 1c, CD30 Fab-multimers brightly stained cells
from the CD30-expressing L1236 cell line in a manner identical to
that of a commercially available anti-CD30 antibody. In order to
analyze the subsequent removal of cell-bound Fab-multimers, cells
were first treated with D-biotin to disrupt the binding between the
Strep-tag on the Fab-fragment and the Strep-Tactin ‘‘backbone’’.
FACS analysis of D-biotin-treated cells showed no remaining PE-
conjugated Strep-Tactin on the cells, indicating efficient and
complete dissociation of multimeric complexes. To visualize
potential residual cell-bound Fab-monomers, D-biotin-treated
cells were washed and subsequently incubated with fresh
(uncomplexed) Strep-Tactin-PE. Based on this sensitive detection
method, we could not identify any remaining Fab-fragments on
the cell surface, indicating that the cell labeling was fully reversible.
Efficient re-staining of liberated cells with anti-CD30 Fab-multi-
mers also excluded the possibility that remaining D-biotin
interfered with Strep-Tactin-PE rebinding through blockade of
Strep-tag binding sites in the subsequent detection steps. These data
demonstrate that multimerization of low affinity Fab-monomers
can be used to generate fully reversible staining probes.
Engineering of reversible Fab-multimers by mutations
In order to generate reversible staining reagents from a broad
spectrum of parental antibodies or for different antigens, it is
necessary to lower binding when monomeric Fab-fragments are of
too high affinity. In order to test whether this can be generally
achieved by the introduction of specific amino acid exchanges, we
generated recombinant Fab-fragments derived from an anti-CD4
antibody with a known high Fab binding affinity (KD value of
29 nM [13B8.2], as previously determined by surface plasmon
resonance [20]). In addition, we generated recombinant Fab-Strep-
tag fusion proteins containing mutations that have been described
to broadly change affinities (KDs ranging from low affinity,
KD=16.9 mM [mutant 3], to intermediate KDs of 0.8 mM [for
mutant 1] and 6.3 mM [mutant 2]) [20]. Site directed amino acid
substitutions were only introduced within the framework of heavy
Clinical Multiparameter Cell Sorting
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variable CDR regions. For staining and dissociation experiments,
we incubated 5610
6 PBMCs with the respective anti-CD4 Fab-
multimer complexes or with the corresponding Fab-monomers
(the latter not complexed with Strep-Tactin). Whereas the Fab-
mutants showed essentially equal staining signals when multi-
merized, only the 13B8.2 Fab-fragment and to a minor extent,
mutant 1, which exhibited higher affinities, were able to bind to
their antigen in a monomeric state (Fig. 2, first column). After D-
biotin-mediated disruption of the multimeric complexes, the cells
were probed for residual surface-bound Fab-fragments. As
expected from the monomer staining experiments, no remaining
Fab-monomers could be detected for mutants 2 and 3, whereas
substantial residual cell surface presence of the wildtype and, to a
minor extent mutant 1 was observed. For mutants 2 and 3, cells
could be efficiently re-stained using secondary Fab-multimer
labeling.
In addition to flow cytometry-based analysis, complete removal
of Fab-multimers was assessed by western blot analysis. Confirm-
ing the highly sensitive FACS results (Fig. S2), we could not detect
Fab-fragments in either the supernatant or the pellet fraction after
Figure 1. Principle of reversible Fab-multimer staining. (a) Schematic overview of sequential positive cell enrichment addressing a subset
within complex cell mixtures that can only be defined by combined expression of three markers ‘A’, ‘B’, and ‘C.’ Three serial enrichment steps allow
exclusive purification of the target population. (b) Illustration of the basic principle of reversible Fab-multimers. Low affinity-modified Fab fragments
are reversibly multimerized by Streptag-Strep-Tactin complexation. Subsequent treatment of stained cells with D-biotin mediates destruction of the
Fab-multimer complex and results in spontaneous dissociation and complete removal of all (monomeric) components from the target cell surface. (c)
Experimental proof-of-concept for fully reversible Fab-multimer staining. CD30-positive cells from the L1236 cell line were stained with either a
monoclonal antibody (left dot plot) or cognate PE-labeled Fab-multimers and analyzed either before (second left column) or after treatment with D-
biotin (middle column). Remaining Fab-monomers were then detected after subsequent washing steps using fresh PE-labeled Strep-Tactin (second
right column). Secondary Fab-multimer staining of reversibly stained cells served as control (right column). Only live (PI
negative) L1236 cells are shown
(dead cell gating is shown in the bottom row). Numbers in dot plots indicate the percentage of cells within gates.
doi:10.1371/journal.pone.0035798.g001
Figure 2. Binding characteristics required for reversible Fab-multimer staining. FACS analysis of anti-CD4 Fab-multimer staining with
different anti-CD4 Fab mutants with decreasing affinities. PBMCs were stained with the respective PE-labeled anti-CD4 Fab-multimers and analyzed
either before (second column) or after treatment with D-biotin (third column). Remaining Fab-monomers were then detected after subsequent
washing steps using (uncomplexed) PE-labeled Strep-Tactin (fourth column). Secondary Fab-multimer staining of reversibly stained cells served as
control (right column). Alternatively, cells were incubated with monomeric Fab-fragments, washed and subsequently analyzed after staining with
Strep-Tactin (left-most column). Live CD3
+ T cells are shown. Numbers in the dot plots indicate the percentage of cells within gates.
doi:10.1371/journal.pone.0035798.g002
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reagents during the staining and release procedure.
In summary, these data demonstrate that engineering of Fabs
with variable binding affinities can be achieved by the introduction
of amino acid changes. Besides the shown CD4 Fab-fragments,
fully reversible Fab-fragments for all other target antigens used in
this manuscript could be generated as described above. In rare
occasions (monomeric) wildtype Fab-fragments already displayed a
sufficiently low intrinsic affinity resulting in their spontaneous
release. Fab-fragments – even when modified to have quite low
binding affinities – can preserve superb staining qualities as
multimers in a manner similar to the parental antibodies. Most
important and in contrast to monoclonal antibodies, low affine
Fabs can be completely removed from the surface of labeled cells.
Sequential magnetic enrichment of central memory T
cells
Reversible Fab staining was developed to enable positive
enrichment of cell populations that need to be defined via multiple
surface markers. To test this, we decided to establish a protocol for
the enrichment of CD8
+ central memory T cell (TCM), which are
characterized by co-expression of CD8, CD62L and CD45RO
whilst being negative for CD45RA. An initial attempt by our
laboratories to enrich TCM used currently available non-reversible
reagents, and involved depletion of cells carrying a number of
exclusion markers (CD4, CD14, CD45RA) followed by a single
positive enrichment step for CD62L expressing cells (Fig. S4). The
yield of TCM (% of the number of purified target cells in relation to
the number of target cells in the original sample) in the final
product averaged 25%, which is expected when considering a cell
loss of approximately 50% for each processing step. Interestingly,
the yields varied substantially from donor to donor, which might
be explained by variable expression patterns (from bright to
intermediate to low/negative) of some markers, especially CD62L.
Unfortunately, the purities of TCM in the final cell product were
suboptimal (mean 36%), mainly due to contaminating CD13
+
basophilic granulocytes of which the majority expresses CD62L
but lack the three markers that were targeted with the depleting
antibodies (Fig. S4). Therefore, further improvement of this
protocol for clinical TCM purification would require at least the
addition of anti-CD13 antibody into the depletion cocktail. For
clinical applications, all antibodies (here at least 5) have to be
generated under GMP conditions, illustrating the financial,
technical and regulatory limitations of current technologies even
for this relatively straightforward application.
To evaluate the potential to purify TCM using reversible staining
reagents, we generated Fab-Streptamers for the surface markers
CD8, CD62L and CD45RA that exhibited fully reversible staining
(Fig. S3). The purification procedure consisted of 3 steps, starting
with 2 positive enrichment cycles for CD8 and CD62L, followed
by one depletion cycle to eliminate CD45RA
+ cells. The
performance of the purification for each single step (including all
negative and positive fractions) is summarized in Fig. 3a. In the
example, the final cell product reached a high purity of .95%
CD8
+ CD45RO
+/CD45RA
2 CD62L
+ TCM (Fig. 3a, b), and
these high purities of TCM were obtained in independent
experiments with PBMC derived from five different donors. The
cell yields were very similar to the ‘non-reversible’ protocol (Fig.
S4), averaging 25% although with high variability in different
donors (Fig. 3b). This demonstrates that reversible Fab-multimers
can be effectively implemented into serial enrichment procedures
to reliably enrich TCM to very high purities using only 3 reagents
that fulfill already the criteria for cell separation under GMP
conditions.
Sequential magnetic enrichment of regulatory T cells
Naturally occurring regulatory T cells (nTregs) have emerged as
a promising population for therapy of autoimmune and alloim-
mune diseases. Therefore, isolation of minimally manipulated and
highly functional Tregs represents a major goal for cell therapeutic
approaches. Although there is debate on which marker combina-
tion is best for clinical nTreg purification, it is clear that only a
combination of multiple markers can define this relatively rare cell
subset. We generated extensive data demonstrating that the
staining combination of CD4
+, CD25
+, CD45RA
+ defines a highly
pure nTreg population that maintains its phenotype and function
even upon in vitro expansion to large cell numbers
14. Currently,
procedures for nTreg enrichment (for research use only) are based
on the depletion of non-Treg cells using a complex antibody
cocktail (including anti-CD8, CD14, CD16, CD19, CD36, CD56,
CD123, TCRcd, Glycophorin A, CD45RO, CD49d, CD127),
followed by positive enrichment for CD25
+ cells within the
remaining cell population. Moreover, the large number of
required antibodies makes transfer of this approach to clinical
applications difficult. We speculated that serial positive enrichment
could limit the reagents required for nTreg purification to just
three (CD4, CD25, CD45RA). In addition to the already
described reversible reagents for CD4 and CD45RA (Fig. 2 and
3), we completed the panel by generation of a reversible anti-
CD25 Fab-fragment (Fig. S3b). Fig. 4a summarizes the first serial
positive enrichment protocol with reversible reagents for these
three different markers (including all negative and positive
fractions). The panel of control stainings nicely demonstrates that
after each purification step the positive selection marker must have
been completely removed, as the following enrichment does not
show any enrichment bias towards the previously used marker. In
the example, a high purity of .90% CD4
+ CD45RA
+ CD25
+ cells
was achieved in the final product (Fig. 4a, d), and these cells
homogeneously expressed Foxp3 (Fig. 4b). Such high purities of
nTreg preparations were reproducibly obtained in independent
experiments using PBMCs derived from five different donors.
Yields often exceeded the expectation of 12.5% when considering
Figure 3. Serial magnetic cell enrichment of central memory T cells. (a) Serial magnetic enrichment of CD8
+CD62L
+CD45RA
neg central
memory T cells from fresh PBMCs. Cells were first incubated with anti-CD8 Fab-multimers conjugated with Strep-Tactin-functionalized magnetic
beads in order to pre-select CD8
+ cells. The resulting positive fraction was then treated with D-biotin and washed to remove all anti-CD8 reagents. In
a second step, CD62L positive T cells were enriched from the pre-selected CD8
+ T cell pool via specific anti-CD62L Fab bound to Strep-Tactin coated
magnetic beads and subsequently liberated from the selection reagents as described above. In a final step CD45RA
+ cells were depleted from the
pre-enriched CD8
+CD62L
+ cell population using CD45RA specific Fab-multimers conjugated to Strep-Tactin-coated beads. Living lymphocytes in the
respective fractions of each selection step are shown. One representative experiment from five independent blood donors is shown. (b) Overlay of
the enriched CD8
+CD62L
+CD45RA
neg cell population (black dots) derived from serial magnetic selection as shown in (a) and the corresponding
starting population (underlying grey dots). (c) Summary of cell purities obtained within each purification step of multiparameter magnetic bead-
based TCM purifications as performed in (a) with PBMCs derived from 5 different blood donors (left graph, mean values are indicated). In the right
graph, yields (in %) of the target TCMs are shown; mean value is indicated. For all samples analyzed by flow cytometry, at least 50.000 events have
been acquired.
doi:10.1371/journal.pone.0035798.g003
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35798Figure 4. Serial magnetic cell enrichment of naturally occurring regulatory T cells. (a) Serial positive magnetic enrichment of
CD4
+CD25
+CD45RA
+ regulatory T cells (nTregs) from PBMCs. For pre-selection of CD4
+ cells, PBMCs were first incubated with anti-CD4 Fab-multimers
conjugated with Strep-Tactin-functionalized magnetic beads. The resulting positive fraction was then liberated from surface-bound label by D-biotin
treatment and washed to remove anti-CD4 reagents. The second purification step comprised the selection for CD25 positive cells from the pre-
selected CD4
+ cell pool via specific anti-CD25 Fab bound to Strep-Tactin coated magnetic beads. Cell bound reagents were again removed from the
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35798a cell loss of approximately 50% per enrichment step (Fig. 4).
Performing suppression assays as described previously [14],
nTregs purified with reversible reagents were characterized by
potent suppressive activity on in vitro stimulated responder T cells
(Fig. S5). We believe that this first example of a triple serial positive
enrichment protocol demonstrates the potential of the novel
reversible Fab-mutlimer technology for isolation of low frequency
cell subsets that can only be distinguished by multiple markers.
Discussion
We describe here the development of a novel, fully reversible
cell staining platform that enables serial positive enrichment over
multiple cell surface markers. Our data shows the utility of this
platform for the purification of CD8
+ central memory T cells
(TCM) and naturally occurring regulatory T cells (nTregs),
illustrating the potential of Fab-multimers for clinical cell
separation in immunotherapy, and to overcome limitations of
current techniques.
Most clinical cell sorting applications are currently based on
reagents conjugated to paramagnetic beads. Very small beads, in
the nano-particle range, are used for positive enrichment of
desired cell populations for clinical application, the best example
being CD34
+ stem cells [28]. However, the relatively long
duration of these processing procedures, the requirement for
specialized equipment (reagents, columns, instruments), and
potential problems caused by remaining bead conjugates on
positively enriched cell populations are limitations. Larger beads
(in the mm range), which can be used with technically less
complicated and rapid cell processing procedures, are currently in
clinical use only for cell depletion, because the co-transfer of larger
beads into patients entails significant risk. The reversible multimer
technology overcomes this problem, since the bead conjugates can
be readily and fully removed from the purified cell population,
independent of their size. In fact, all purification procedures
described in this report were performed with paramagnetic beads
of 1 mm in diameter, and marker/bead binding cells were retained
using a permanent magnet in close proximity to the cell solution.
This procedure can easily be transferred to different cell processing
devices, including collection bags that are often used for clinical
cell therapy. Therefore, we believe that the ‘‘Streptamers’’ not only
provides a novel option for purifying defined cell populations by
serial positive enrichment, but also has the potential to vastly
simplify and accelerate clinical cell processing procedures.
Multiparameter cell selection is a domain of flow cytometry-
based cell sorting, but there is still a lack of routine applicability for
clinical use. In a few locations worldwide, scientific groups and
companies in close exchange with local authorities are currently
installing flow cytometry cell sorters into GMP facilities (e.g. the
Influx from BD) paving the way for upcoming first clinical trials.
However, there are still many technical obstacles for bringing flow
cytometry into clinical cell sorting, with one of the most prominent
being remaining surface bound fluorochrome-conjugated staining
reagents left on the purified cell population. A major advantage of
reversible staining for clinical applications is that it avoids the co-
infusion of labeling reagents such as monoclonal antibodies,
fluorochromes or magnetic beads into patients. The recent
fatalities that occurred following administration of a stimulatory
CD28 superagonist illustrate the potential for unanticipated
adverse events, and have made it essential that reagents with the
potential to bind cell surface molecules that can alter cell function
undergo laborious and costly pre-clinical in vivo testing for
regulatory approval [29]. Reversible staining with Fab-multimers
can also overcome side effects that might be mediated by the
labeling regents themselves, even when signaling molecules are the
targets for cell selection ([30,31] and data not shown). The
prevention of cell changes as a consequence of binding cell surface
markers, which are even more difficult to monitor and predict
when various labels are combined and bound to cells, is of general
importance not only for clinical cell sorting, but also for
interpreting the results of basic research studies that involve the
transfer of functional cell populations. The (one dimensional)
reversible MHC-Streptamer [3] purification of antigen-specific T
cells for clinical adoptive therapy was recently approved by
European (European Medicines Agency) and German (Paul-
Ehrlich-Institute) regulatory authorities as ‘minimally manipulat-
ed’, because when used under quality-controlled cell processing
protocols, complete removal of the labeling reagents from the cell
product was reliably demonstrated. Since the novel Fab-multimers
described in the present study fulfill identical criteria, it is very
likely that cell populations purified by serial positive enrichment
will similarly be classified as ‘minimally manipulated’. This would
substantially facilitate the implementation of multiparameter cell
selection by serial positive enrichment into clinical applications.
Supporting Information
Figure S1 Organization of the Fab encoding operon.
Schematic overview of the operon encoding antibody Fab-
fragments. The first cistron encodes the chimeric heavy chain,
consisting of the respective VH fragment, the human IgG1
constant domain and the C-terminal OneSTrEPtag. The VH
domain is N-terminally fused to the ompA signal peptide. The
second cistron encodes the VL domain N-terminally fused to the
phoA leader peptide and C-terminally followed by the human k
constant domain.
(TIFF)
Figure S2 Reversibility of Fab-multimer staining. West-
ern blot analysis of the removal of Fab-multimers generated with
different anti-CD4 Fab-mutants (a) or the anti-CD25 Fab mutant
(b). PBMCs were incubated with the respective CD4 or CD25 Fab-
multimers, and following D-biotin treatment and subsequent
washing, the cells were lysed, and parts of the liquid and pellet
fractions were analyzed for remaining Fab-monomers using highly
specific anti-OneSTrEPtag antibodies. The direct application of
purified Fab-protein (a, first lane) served as a loading control. Flow
cytometry-based control multimer stainings (solid line) compared to
unstained cells (tinted histogram) are shown below to demonstrate
that cells had been properly stained before dissociation.
(TIFF)
resulting positive fraction by addition of D-biotin. In a third purification step, CD45RA
+ cells were isolated from the enriched CD4
+CD25
+ cell
population by using CD45RA-specific Fab-multimers conjugated to Strep-Tactin-coated magnetic beads. Living lymphocytes in the respective
fractions of each selection step are shown. One representative experiment from five independent blood donors is shown. (b) Intracellular FoxP3
staining of triple positive enriched CD4
+CD25
+CD45RA
+ regulatory T cells. (c) Overlay of the enriched CD4
+CD25
+CD45RA
+ cell population (black
dots) derived from serial magnetic selection as shown in (a) and the corresponding starting population (underlying grey dots). (d) Summary of cell
purities obtained within each purification step of multiparameter magnetic bead-based nTregs purifications as performed in (a) with PBMCs derived
from 5 different blood donors (left graph, mean values are indicated). In the right graph, yields (in %) of the target nTregs are shown; mean value is
indicated. For all samples analyzed by flow cytometry, at least 50.000 events have been acquired.
doi:10.1371/journal.pone.0035798.g004
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e35798Figure S3 Reversible staining by CD8, CD25, CD45RA
and CD62L Fab-multimers. FACS analysis of freshly isolated
PBMCs stained with PE-labeled anti- CD8 (a), anti-CD25 (b),
anti-CD45RA (c) and anti-CD62L Fab-multimers. Cells were
analyzed either before (first column) or after (second column)
treatment with D-biotin. After subsequent washing steps, remain-
ing Fab-monomers were detected using (uncomplexed) PE-labeled
Strep-Tactin (third column). Secondary Fab-multimer staining of
reversibly stained cells served as control for successful removal of
D-biotin (right column). Live CD3
+ T cells (a, b and d) or
CD14
2CD19
2 cells (c) are shown. The numbers in dot plots
indicate the percentage of cells within gates.
(TIFF)
Figure S4 Enrichment of TCM using sequential deple-
tion and positive selection of cells with non-reversible
reagents. a). PBMC were labelled with clinical grade anti CD4,
CD45RA and anti CD14 mAb conjugated to paramagnetic beads
(Miltenyi Biotec), and the labelled cells were removed using the
AutoMACS or CliniMACS device. CD62L
+ cells were then
enriched from the remaining depleted fraction by a subsequent
positive selection with a clinical grade biotin conjugated anti-
CD62L mAb (DREG56 clone, kindly provided by City of Hope
Cancer Research Center) and anti-biotin microbeads (Miltenyi
Biotec, Germany). The panels show staining of live cells for CD3,
CD8, CD62L, CD45RA, CD45RO, CD4, and CD14 in PBMC
(before), and in the depleted and positively selected fractions. In
the example, the depleting antibodies were highly effective in
removing CD4
+, CD14
+, and CD45RA+ cells, and CD8
+ TCM
were enriched to 35% in the final cell product. The large fraction
(55%) of CD3
2CD8
2 cells in the final cell product (inset) are
CD13
+CD62L
+ cells that are not removed by the depletion
cocktail and are consistent with basophils based on staining with
an extended panel of antibodies. b) Overlay of the enriched
CD8
+CD62L
+CD45RA
neg cell population (black dots) after the
two-step selection and the corresponding starting population
(underlying grey dots). c) Summary of purity and yield of CD8
+
TCM from multiple experiments. The frequency of CD8
+ TCM in
PBMC (bold) and after enrichment (open) for each donor is
indicated by a circle. The phenotype of the major contaminating
cells (CD8
+CD62L
2 and CD13
+CD62L
+) in the cell product is
shown.
(TIFF)
Figure S5 Functionality of Fab-multimer-isolated regu-
latory T cells. Suppressive activity of regulatory T cells enriched
by serial Fab-multimer staining (see Fig. 4). Suppression was
determined after polyclonal stimulation in a CFSE dilution assay
at a Treg:T responder cell ratio of 2:1, n=3. Sort purities were
usually above 95%. The vertical line separates divided from
undivided cells.
(TIFF)
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